Senate Bill 1391
116th Congress(2019-2020)
Fair Accountability and Innovative Research Drug Pricing Act of 2019
Introduced
Introduced in Senate on May 9, 2019
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1391
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No Senate votes have been held for this bill.
Summary
Fair Accountability and Innovative Research Drug Pricing Act of 2019
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
May 9, 2019
Sort by most recent
05/09/2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
05/09/2019
Introduced in Senate
Public Record
Record Updated
Feb 8, 2022 11:21:46 PM